2024
Proenkephalin Improves Cardio-Renal Risk Prediction in Acute Coronary Syndromes: The KID-ACS Score
WENZL, Florian A, Peizhi WANG, Mattia ARRIGO, Jiří PAŘENICA, Donald J L JONES et. al.Základní údaje
Originální název
Proenkephalin Improves Cardio-Renal Risk Prediction in Acute Coronary Syndromes: The KID-ACS Score
Autoři
WENZL, Florian A, Peizhi WANG, Mattia ARRIGO, Jiří PAŘENICA, Donald J L JONES, Francesco BRUNO, Daniel TARNWSKI, Oliver HARTMANN, Luboš BOUČEK, Fabian LANG, Slayman OBEID, Andreas SCHOBER, Simon KRALER, Alexander AKHMEDOV, Florian KAHLES, Alexander SCHOBER, Kok Weng OW, Stefano MINISTRINI, Giovanni G CAMICI, Andreas BERGMANN, Luca LIBERALE, Jiri JARKOVSKY, Victor SCHWEIGER, Jatinderpal K SANDHU, Arnold von ECKARDSTEIN, Christian TEMPLIN, Olivier MULLER, Tomáš ONDRÚŠ, Olic JANET-JACQUELINE, Marco ROFFI, Lorenz RÄBER, Thong H CAO, Carsten G JUNGBAUER, Leong L NG, Alexandre MEBAZAA a Thomas F LÜSCHER
Vydání
European Heart Journal, OXFORD, OXFORD UNIV PRESS, 2024, 0195-668X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 39.300 v roce 2022
Organizační jednotka
Lékařská fakulta
UT WoS
001318498800001
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 5. 11. 2024 09:49, Mgr. Tereza Miškechová
Anotace
V originále
Background and Aims Circulating proenkephalin (PENK) is a stable endogenous polypeptide with fast response to glomerular dysfunction and tubular damage. This study examined the predictive value of PENK for renal outcomes and mortality in patients with acute coronary syndromes (ACS). Methods Proenkephalin was measured in plasma in a prospective multicentre ACS cohort from Switzerland (n=4787) and in validation cohorts from the UK (n=1141), Czechia (n=927), and Germany (n=220). A biomarker-enhanced risk score (KID-ACS score) for simultaneous prediction of in-hospital acute kidney injury (AKI) and 30-day mortality was derived and externally validated. Results On multivariable adjustment for established risk factors, circulating PENK remained associated with in-hospital AKI (per log2 increase: adjusted odds ratio [OR] 1.53, 95% confidence interval [CI] 1.13–2.09, P=0.007) and 30-day mortality (adjusted hazard ratio [HR] 2.73, 95% CI 1.85–4.02, P<0.001). The KID-ACS score integrates PENK and showed an area under the receiver operating characteristic curve (AUC) of 0.72 (95% CI 0.68–0.76) for in-hospital AKI, and of 0.91 (95% CI 0.87–0.95) for 30-day mortality in the derivation cohort. Upon external validation, KID-ACS achieved similarly high performance for in-hospital AKI (Zurich: AUC 0.73, 95% CI 0.70–0.77; Czechia: AUC 0.75, 95% CI 0.68–0.81; Germany: AUC 0.71, 95% CI 0.55–0.87) and 30-day mortality (UK: AUC 0.87, 95% CI 0.83–0.91; Czechia: AUC 0.91, 95% CI 0.87–0.94; Germany: AUC 0.96, 95% CI 0.92–1.00) outperforming the CA-AKI score and the GRACE 2.0 score, respectively. Conclusions Circulating PENK offers incremental value for predicting in-hospital AKI and mortality in ACS. The simple 6-item KID-ACS risk score integrates PENK and provides a novel tool for simultaneous assessment of renal and mortality risk in patients with ACS.